Skip to main content

Biogen FLIXABI revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

FLIXABI revenue at Biogen came to $6.4M for the quarter to 30 Sep 2026, down 58.2% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$16.7MDec 2023$17.8MMar 2024$13.1MJun 2024$16.2MSep 2024$16.1MDec 2024$13.1MMar 2025$14.3MJun 2025$15.3MSep 2025$9.9MDec 2025$10.5MMar 2026$8.1MJun 2026$6.4MSep 2026
Biogen FLIXABI revenue, every reported period
Period endingFLIXABI revenueChange on a yearFiled
30 Sep 2026$6.4Mdown 58.2%28 Oct 2026
30 Jun 2026$8.1Mdown 43.4%29 Jul 2026
31 Mar 2026$10.5Mdown 19.8%29 Apr 2026
31 Dec 2025$9.9Mdown 38.5%6 Feb 2026
30 Sep 2025$15.3Mdown 5.6%30 Oct 2025
30 Jun 2025$14.3Mup 9.2%31 Jul 2025
31 Mar 2025$13.1Mdown 26.4%1 May 2025
31 Dec 2024$16.1Mdown 3.6%12 Feb 2025
30 Sep 2024$16.2Mdown 19.8%30 Oct 2024
30 Jun 2024$13.1Mdown 34.8%1 Aug 2024
31 Mar 2024$17.8Mdown 12.7%24 Apr 2024
31 Dec 2023$16.7Mdown 13.5%14 Feb 2024
30 Sep 2023$20.2Mup 6.3%8 Nov 2023
30 Jun 2023$20.1Mdown 2.0%25 Jul 2023
31 Mar 2023$20.4Mdown 9.3%25 Apr 2023
31 Dec 2022$19.3Mdown 19.6%15 Feb 2023
30 Sep 2022$19.0Mdown 22.8%25 Oct 2022
30 Jun 2022$20.5Mdown 19.0%20 Jul 2022
31 Mar 2022$22.5Mdown 11.8%3 May 2022
31 Dec 2021$24.0Mdown 8.0%3 Feb 2022
30 Sep 2021$24.6Mdown 10.5%20 Oct 2021
30 Jun 2021$25.3Mup 22.8%22 Jul 2021
31 Mar 2021$25.5Mup 7.6%22 Apr 2021
31 Dec 2020$26.1Mup 43.4%3 Feb 2021
30 Sep 2020$27.5Mup 49.5%21 Oct 2020
30 Jun 2020$20.6Mup 22.6%22 Jul 2020
31 Mar 2020$23.7Mup 61.2%23 Apr 2020
31 Dec 2019$18.2Mup 30.0%6 Feb 2020
30 Sep 2019$18.4Mup 61.4%22 Oct 2019
30 Jun 2019$16.8Mup 50.0%24 Jul 2019
31 Mar 2019$14.7Mup 122.7%24 Apr 2019
31 Dec 2018$14.0M—6 Feb 2019
30 Sep 2018$11.4Mup 418.2%23 Oct 2018
30 Jun 2018$11.2Mup 489.5%24 Jul 2018
31 Mar 2018$6.6M—24 Apr 2018
30 Sep 2017$2.2M—24 Oct 2017
30 Jun 2017$1.9M—25 Jul 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.